{
  "abstract": "Purpose: Brain metastases affect many patients with solid tumor malignancies. Treatments include surgery, radiation, immunotherapy, and CNS-penetrating chemotherapy. Nonetheless, rates of CNS-related tumor death remain high. Local recurrence after radiosurgery and lesions with a V12 too high for radiosurgery present a particular challenge. The VIGILANT (Vigilant Observation of GLIADEL Wafer Implant) registry prospectively examined use and efficacy of carmustine-releasing wafers which includes patients with brain metastases [1]. Here we present a retrospective analysis of patients with brain metastasis from the VIGILANT registry.\n\nMethods: Forty-seven patients were observed after surgical resection of brain metastasis and GLIADEL implantation at Wake Forest Baptist Medical Center. Thirty-eight patients underwent treatment for local recurrence following radiosurgery. Nine had lesions treated that were deemed too large for successful primary radiosurgery. Patients were evaluated primarily for overall survival (OS) and progression free survival (PFS) from the date of surgery, and secondarily for adverse events and local progression.\n\nResults: Median OS was 23 months. Of 25 deaths, 7 (28%) met criteria for CNS-tumor related etiology. 24 (51.1%) patients had progression during follow up, 6 (12.8%) had local progression. 2 (4.3%) overall had local progression that required additional neurosurgical treatment. Of 9 patients not previously treated with radiosurgery, 4 (44.4%) had no progression. Of 5 patients who received GLIADEL as their upfront cranial intervention, none had local recurrence. 43 patients had adverse events; 2 considered possibly GLIADEL related.\n\nConclusions: In this single-institution retrospective analysis of prospectively collected registry data, patients undergoing resection and carmustine wafer implantation after prior radiosurgery or for lesions considered unsuitable for primary radiosurgery had favorable observed survival (OS 23 months), intracranial progression (1-year local progression rate of 12%), and minimal related adverse-event outcomes.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11060-026-05871-2.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurological Surgery, Wake Forest University School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157 USA",
    "Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC USA",
    "Department of Radiation Oncology, Wake Forest University School of Medicine, Winston- Salem, NC USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Eleanor C. Smith"
    },
    {
      "affs": [
        0
      ],
      "name": "Jared M. Kaplan"
    },
    {
      "affs": [
        0
      ],
      "name": "Bryan T. Mott"
    },
    {
      "affs": [
        1
      ],
      "name": "Carol Kittel"
    },
    {
      "affs": [
        1
      ],
      "name": "Molly Ehrig"
    },
    {
      "affs": [
        2
      ],
      "name": "Christina K. Cramer"
    },
    {
      "affs": [
        0
      ],
      "name": "Jaclyn J. White"
    },
    {
      "affs": [
        0
      ],
      "name": "Stephen B. Tatter"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bym5gv9mzn2tb.bib",
  "cited_by": 0,
  "doi": "10.1007/s11060-026-05871-2",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13755031/",
  "id": "bym5gv9mzn2tb",
  "issns": [
    "0167-594X",
    "1573-7373"
  ],
  "landing_url": "https://doi.org/10.1007/s11060-026-05871-2",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2730|Brain Metastases and Treatment"
    ]
  ],
  "openalex": "W7212145588",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s11060-026-05871-2.pdf",
  "pmcid": "PMC13755031",
  "pmid": "43012930",
  "published": "2026-11-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/bym5gv9mzn2tb.ris",
  "sources": [
    {
      "first_seen": "2026-11-15T12:23:55Z",
      "native_id": "PMC13755031",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s11060-026-05871-2"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Brain Metastases and Treatment",
      "subfield": "oncology"
    }
  ],
  "title": "Carmustine-releasing wafers for brain metastasis: single institution experience and results of the VIGILANT registry",
  "title_text": "Carmustine-releasing wafers for brain metastasis: single institution experience and results of the VIGILANT registry",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:21:11Z",
  "url": "https://research.draconitic.com/paper/bym5gv9mzn2tb",
  "venue": "Journal of Neuro-Oncology",
  "versions": []
}